PrEP Access and Coverage Act of 2026
- Sponsor
- Rep. Takano, Mark [D-CA-39]
- Committees
- Education and Workforce Committee (primary)
- Last action
- Mar 5, 2026
Bottom line
The bill aims to eliminate financial and discriminatory barriers to HIV prevention medication and services across all major health care sectors and insurance types in the U.S. to reduce HIV transmission.
What it actually does
This bill mandates comprehensive, no-cost coverage for HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) drugs and related services across various health insurance programs, including private insurance, the Federal Employees Health Benefits Program (FEHBP), Medicaid, CHIP, Medicare, Department of Veterans Affairs (VA), Department of Defense (DOD), and the Indian Health Service. It also prohibits discrimination in life, disability, and long-term care insurance based on an individual's use of PrEP, establishes public and provider education campaigns, and creates a grant program to enhance PrEP/PEP access.
Proponents argue
Proponents argue that increasing access to PrEP and PEP without cost-sharing is a critical public health measure to reduce HIV transmission, save lives, and ultimately lower healthcare costs associated with HIV treatment. They emphasize that these medications are highly effective and that removing financial barriers and stigma will help reach underserved communities disproportionately affected by HIV, aligning with national goals to end the HIV epidemic.
Opponents contend
Opponents might raise concerns about the potential financial burden on insurance providers and federal programs, arguing that mandating universal coverage without cost-sharing could lead to increased premiums for private insurance or higher taxes to fund federal programs. Some may also express reservations about federal overreach into insurance markets or state healthcare programs, or question the cost-effectiveness of universal no-cost coverage versus more targeted subsidies.
The bill is moderately complex due to its numerous amendments to existing federal statutes, requiring careful reading to understand its full scope, but it is manageable within a reasonable timeframe for an informed reader.
Section 3(a)(1) and (2)
Mandated No-Cost PrEP Coverage for Private Insurance
This provision amends the Public Health Service Act to require all private health insurance plans, including those previously grandfathered under the Affordable Care Act, to cover all FDA-approved HIV prevention drugs (PrEP), associated administrative fees, laboratory tests, and clinical monitoring without any out-of-pocket costs for the patient. This ensures that individuals with private insurance can access these critical preventive services without financial barriers.
Supporters argue
Supporters argue that this provision removes a significant financial barrier, making PrEP accessible to more people and aligning with public health goals to reduce HIV transmission. They contend that the long-term health benefits and reduced HIV treatment costs outweigh the initial investment.
Critics contend
Critics may argue that this mandate increases regulatory burden and costs for private insurers and employers, which could potentially lead to higher premiums for all policyholders. They might also suggest that market-based solutions are more efficient than federal mandates.
Tradeoffs
The provision navigates the tradeoff between ensuring universal access to a highly effective preventive medication and the potential for increased costs and regulatory burdens on the private health insurance market.
Section 3(a)(3)
Prohibition on Prior Authorization for PrEP
This section amends the Public Health Service Act, the Employee Retirement Income Security Act of 1974 (ERISA), and the Internal Revenue Code to prohibit private health plans from requiring prior authorization before covering PrEP medications and related services. An exception is made: a plan may impose preauthorization for a specific drug if it covers a therapeutically equivalent drug without any preauthorization requirements. This aims to streamline access by removing administrative hurdles.
Section 3(c) and (d)
Mandatory No-Cost PrEP/PEP Coverage for Medicaid and CHIP
This provision amends the Social Security Act to explicitly include HIV prevention services (defined as PrEP drugs, administrative fees, laboratory tests, and clinical follow-up) as a mandatory benefit under both Medicaid and the Children's Health Insurance Program (CHIP). It further prohibits states from imposing any cost-sharing requirements for these services, ensuring that low-income and uninsured individuals covered by these programs have full, free access to HIV prevention.
Section 3(e)
No-Cost PrEP/PEP Coverage for Medicare Beneficiaries
This section amends the Social Security Act to include HIV prevention services under Medicare Part B, mandating coverage without coinsurance or deductibles. Additionally, it eliminates deductibles and all other cost-sharing for PrEP drugs under Medicare Part D. These changes ensure that Medicare beneficiaries, including older adults and individuals with disabilities, have full financial access to HIV prevention medications and associated care.
Section 4
Anti-Discrimination for PrEP Users in Life, Disability, and Long-Term Care Insurance
This section makes it unlawful for life insurance, disability insurance, or long-term care insurance companies to deny coverage, limit benefits, or increase premium rates solely because an individual is taking medication for the purpose of preventing HIV acquisition. It also prohibits precluding an individual from taking PrEP as a condition of receiving such policies. This aims to protect individuals using PrEP from discriminatory practices in these insurance markets.
Section 5
PrEP and PEP Public and Provider Education Campaigns
This section directs the Secretary of Health and Human Services, through the Centers for Disease Control and Prevention (CDC), to establish public education campaigns to increase awareness of PrEP and PEP, counter stigma, and promote their use, especially in communities disproportionately affected by HIV. It also mandates a provider education campaign to increase healthcare professionals' readiness to offer PrEP/PEP, improve their cultural competency, and address stigma associated with these medications. Both campaigns are authorized for appropriations through fiscal year 2030.
Section 7
PrEP and PEP Grant Program
This section establishes a federal grant program, to be administered by the Secretary of HHS, which will award grants to states, territories, Indian Tribes, and directly eligible entities (such as Federally Qualified Health Centers and community-based organizations). These grants are intended to establish and support PrEP and PEP programs, particularly for uninsured and underinsured individuals, and to reduce disparities in access. The program is authorized for appropriations through fiscal year 2030.
This clause states that for the purposes of this Act and any other provision of law, the current recommendations of the United States Preventive Service Task Force (USPSTF) regarding breast cancer screening, mammography, and prevention shall be considered the most current, *other than those issued in or around November 2009*.
Section 3(a)(1)(F)
Why it matters:This appears to be a legislative maneuver to override a specific, controversial 2009 USPSTF recommendation that suggested less frequent mammograms for women in their 40s. By including it in an HIV prevention bill, it might be less visible than if it were a standalone section or part of a bill specifically addressing breast cancer screening, potentially indicating an evasive legislative tactic.
Case for: Supporters of this clause would argue it ensures that more aggressive breast cancer screening guidelines are followed, potentially leading to earlier detection and better outcomes for women, overriding a recommendation perceived as too restrictive or harmful.
Case against: Critics might argue that inserting such a provision into an HIV prevention bill is an inappropriate legislative tactic (a 'rider') and that it undermines the independent, evidence-based recommendations of the USPSTF, setting a precedent for political interference in clinical guidelines.
Estimated impact: Could affect millions of women by influencing insurance coverage for breast cancer screenings, potentially increasing screening rates and associated costs for insurers and the healthcare system.
This section directs the Secretary of Health and Human Services to amend the regulations promulgated under section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) as necessary. The purpose is to ensure that individuals are able to access PrEP benefits under a family plan without any other individual enrolled in such family plan, including a primary subscriber or policyholder, being informed of such use of benefits.
Section 6
Why it matters:This is a critical detail for patient privacy, especially for younger individuals or those in sensitive family situations where disclosure of PrEP use could lead to judgment or conflict. Its placement is standard for regulatory directives, but its importance might be overlooked by those focusing solely on the financial coverage aspects. Its inclusion is a deliberate effort to ensure the effectiveness of the coverage mandates by addressing privacy concerns.
Case for: Proponents argue this is essential to protect patient privacy and encourage PrEP uptake, especially among adolescents and young adults who might fear family judgment or disclosure. Without this, the coverage mandates could be undermined by privacy concerns, preventing individuals from accessing necessary prevention.
Case against: Some might argue that primary policyholders have a right to know about all services covered under their family plan, or that such a provision could create administrative complexities for insurers in managing billing and communication within family plans.
Estimated impact: Could significantly increase PrEP uptake among individuals concerned about family privacy, particularly adolescents and young adults, without a direct fiscal impact but requiring administrative adjustments for insurers and HHS.